



Clover Corporation Limited

ABN 85 003 622 866

24 July 2025

ASX ANNOUNCEMENT

Clover Corporation Limited, Board of Directors Appointment & Retirement

APPOINTMENT

Clover Corporation Pty Limited (ASX: CLV) is pleased to announce the appointment of Ms. Fiona Pearse as Non-Executive Director to its Board of Directors, effective 1 August 2025. An Appendix 3X is attached to this announcement.

Fiona is an experienced Non-Executive Director who has extensive commercial expertise gained from a broad Commercial, Finance and Tax career during almost two decades at complex ASX-listed, global companies BHP Billiton and BlueScope Steel.

Fiona is the current Chair of the Board of U Ethical, one of Australia's largest dedicated ethical Fund Managers. She is also a Non-Executive Director, and Chair of the Risk and Audit Committee of Smart Parking (ASX: SPZ), a rapid growth, global technology and parking business; and a Non-Executive Director of Monash Health, the largest hospital/health service in Victoria with a \$3 billion turnover.

Fiona holds a Bachelor of Economics and a Senior Executive MBA and is a Fellow of CPA Australia, and a Fellow of the Australian Institute of Company Directors.

RETIREMENT

Mr Graeme Billings who has been a Non-Executive Director for the past 12 years will retire at this year's Annual General Meeting. Graeme has contributed strong financial expertise, governance and business insights to the Board and Company. He has chaired the Audit and Risk Committee and served on the Nominations and People & Culture Committees for the past 12 years"

The appointment of Fiona Pearse follows the planned succession of the Board of Directors, with Fiona succeeding Graeme as Chair of Audit & Risk post the Annual General Meeting.

For further information, please contact:

Mr Rupert Harrington – Chairman, Clover Corporation +61 3 8347 5000

Mr Peter Davey – MD & CEO, Clover Corporation +61 3 8347 5000

About Clover Corporation Limited

Clover Corporation is an Australian company listed on the Australian Stock Exchange (ASX:CLV). Clover evolved from being a research and development, manufacturing, and marketing company to one concentrating on forming strategic relationships focused on technology, new product development and commercialisation. Clover's superior microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods and beverages. Developed through extensive research and development, our proprietary technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. All Clover products reach the highest standards of purity, stability, and performance, allowing customers to maximise and deliver nutrition.

For more information about Clover visit www.clovercorp.com.au